^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | FL118 (DDX5 degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sensitivity of colorectal or pancreatic cancers with high DDX5 and mutations in Kras and p53 genes to FL118 treatment.
Published date:
05/28/2020
Excerpt:
FL118 can eliminate the Kras/p53/APC triple-mutated SW620-established CRC tumors in a high percentage of mice at doses of 6 (maximum tolerated dose, MTD), 5, 4, 3, and 2 mg/kg….DDX5, mKras and mp53 appears to be favorable biomarkers for predicting FL118 high efficacy.
DOI:
10.1200/JCO.2020.38.15_suppl.e16102
